Marketing research and data analytics companies and departments that operate as business associates under HIPAA have a bit more leeway in handling disclosure of protected health information during the COVID-19 crisis if the data relates to public health
Adverse event reporting, with which some pharmaceutical and medical device manufacturers require assistance from their marketing research and data analytics departments and partners/vendors, continues during the COVID-19 crisis.
Each time the state of Minnesota has tried to clarify treatment of respondent incentives for the participation of health care practitioners in marketing research sponsored by pharmaceutical manufacturers, companies still end up confused. What do the law, regulations and guidance tell us?
Philadelphia Rejects Bill That Would Have Banned Pharmaceutical Marketing Research with Healthcare Professionals
Legislation in the city of Philadelphia that would have cut off pharmaceutical marketing research with doctors was defeated in the city council yesterday.
As the state legislature considers a bill to prohibit most payments from the pharmaceutical industry to health care providers in connection with their participation in research, a new survey indicates the public health benefits of pharmaceutical marketing research studies of doctors.
Morris Whitcup and Keith LaMattina explore the wearable medical device market, in Alert! magazine
“Patients are lying to their doctors; they are lying to protect their privacy,” stated Kathryn Serkes.
A number of interesting bills have been introduced in Tennessee, Oklahoma, New York, Hawaii, Virginia and Georgia on issues of data sharing, data security, healthcare data privacy, data retention,
South Carolina Senator Daniel B. "Danny" Verdin (R-09) introduced S.J.R.
North Carolina Governor Bev Purdue (D) signed